Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags CD22-4AP

Tag: CD22-4AP

ASH 2020: Positive Interim Phase I Study Results of TRPH-222 in...

Peter Hofland
TRPH-222 (CD22-4AP), an antibody-drug conjugate (ADC) being developed by Triphase, demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients...

New Licensing Agreement Is Expected to Advance Catalent’s Proprietary SMARTag Technology...

ADC Review | Editorial Team
This week, during the annual CPhI World Wide congress and exhibition being held in Barcelona, Spain, June 4 - 6, 2016, Catalent, the leading...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X